BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Sees Large Growth in Short Interest

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) saw a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 111,892 shares, an increase of ∞ from the July 30th total of 0 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average trading volume of 360,667 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th.

BlossomHill Therapeutics Stock Down 1.2%

Shares of BLSM opened at $19.56 on Friday. BlossomHill Therapeutics has a twelve month low of $15.25 and a twelve month high of $20.61.

Insider Buying and Selling

In other BlossomHill Therapeutics news, Director Bihua Chen bought 312,500 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director directly owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This trade represents a 9.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director John P. Schmid bought 6,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $96,000.00. Following the purchase, the director owned 6,000 shares of the company’s stock, valued at $96,000. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.